RC
KLRS

RBF Capital’s Kalaris Therapeutics KLRS Stock Holding History

RBF Capital’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$70.8K Hold
17,391
– – ﹤0.01% 506
2026
Q1 		$100K Hold
17,391
– – ﹤0.01% 476
2025
Q4 		$147K Hold
17,391
– – 0.01% 530
2025
Q3 		$101K Hold
17,391
– – ﹤0.01% 555
2025
Q2 		$46.4K Hold
17,391
– – ﹤0.01% 596
2025
Q1 		$140K Hold
17,391
– – 0.01% 533
2024
Q4 		$168K Sell
17,391
-2,131
-11% -$32.2K 0.01% 513
2024
Q3 		$363K Hold
19,522
– – 0.02% 474
2024
Q2 		$325K Buy
+19,522
New +$345K 0.02% 472

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

RBF Capital's KLRS Position: Q2 2026 in Review

RBF Capital held its Kalaris Therapeutics (KLRS) position steady in Q2 2026 at 17,391 shares worth $70.8K. The position accounts for ﹤0.01% of the portfolio, ranked #506.

RBF Capital first reported a position in KLRS in Q2 2024 and has held it in 9 quarters since. The position peaked at $363K in Q3 2024. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • RBF Capital held 17,391 shares of Kalaris Therapeutics worth $70.8K as of Q2 2026.
  • RBF Capital left its Kalaris Therapeutics share count unchanged in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of RBF Capital's portfolio in Q2 2026, its #506 holding.
  • RBF Capital first reported a position in Kalaris Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • RBF Capital's Kalaris Therapeutics position peaked at $363K in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.